Innoviva, Inc. (NASDAQ:INVA) Shares Bought by US Bancorp DE

US Bancorp DE boosted its holdings in shares of Innoviva, Inc. (NASDAQ:INVA) by 24.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,875 shares of the biotechnology company’s stock after purchasing an additional 566 shares during the quarter. US Bancorp DE’s holdings in Innoviva were worth $56,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Boston Partners raised its holdings in Innoviva by 90.3% in the 1st quarter. Boston Partners now owns 391,456 shares of the biotechnology company’s stock valued at $5,966,000 after buying an additional 185,784 shares during the period. O Shaughnessy Asset Management LLC grew its stake in shares of Innoviva by 108.8% in the first quarter. O Shaughnessy Asset Management LLC now owns 73,066 shares of the biotechnology company’s stock valued at $1,114,000 after buying an additional 38,080 shares in the last quarter. Victory Capital Management Inc. raised its holdings in shares of Innoviva by 63.1% in the 2nd quarter. Victory Capital Management Inc. now owns 135,755 shares of the biotechnology company’s stock valued at $2,226,000 after buying an additional 52,523 shares during the period. BOKF NA lifted its stake in Innoviva by 180.5% during the 2nd quarter. BOKF NA now owns 46,377 shares of the biotechnology company’s stock worth $761,000 after acquiring an additional 29,846 shares in the last quarter. Finally, Caxton Associates LP lifted its stake in Innoviva by 204.5% during the 2nd quarter. Caxton Associates LP now owns 108,277 shares of the biotechnology company’s stock worth $1,776,000 after acquiring an additional 72,716 shares in the last quarter. 99.12% of the stock is owned by hedge funds and other institutional investors.

Innoviva Stock Performance

Shares of INVA stock opened at $18.90 on Monday. The stock’s 50-day moving average price is $19.64 and its 200 day moving average price is $17.99. The company has a quick ratio of 1.64, a current ratio of 1.79 and a debt-to-equity ratio of 0.38. The stock has a market capitalization of $1.18 billion, a PE ratio of 27.39 and a beta of 0.57. Innoviva, Inc. has a 52-week low of $13.41 and a 52-week high of $21.28.

Innoviva (NASDAQ:INVA) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.27 by ($0.25). Innoviva had a return on equity of 20.84% and a net margin of 18.31%. The business had revenue of $89.51 million for the quarter. As a group, equities research analysts forecast that Innoviva, Inc. will post 0.33 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on INVA. StockNews.com downgraded Innoviva from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 6th. Cantor Fitzgerald restated an “overweight” rating on shares of Innoviva in a research note on Tuesday, July 30th.

About Innoviva

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.